Back to Search Start Over

Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer.

Authors :
Yokoyama Y
Futagami M
Watanabe J
Sato N
Terada Y
Miura F
Sugiyama T
Takano T
Yaegashi N
Kojimahara T
Kurachi H
Nishiyama H
Fujimori K
Tase T
Mizunuma H
Source :
Molecular and clinical oncology [Mol Clin Oncol] 2014 Mar; Vol. 2 (2), pp. 212-218. Date of Electronic Publication: 2013 Dec 10.
Publication Year :
2014

Abstract

The standard postoperative chemotherapy for epithelial ovarian cancer is a combination therapy including platinum and taxanes. The aim this study was to investigate the degree of platinum sensitivity in patients with relapsed epithelial ovarian cancer according to the treatment-free interval (TFI) and the histological tumor type. The medical records of 405 patients diagnosed with stage III/IV ovarian cancer, including 107 patients who relapsed after attaining a clinical complete response with first-line treatment, were retrospectively reviewed. The degree of platinum sensitivity was assessed by comparing the progression-free survival (PFS) following the second-line treatment. In patients with serous/endometrioid adenocarcinoma who were treated with platinum following relapse, there were significant differences in the PFS between the following groups of patients: those who relapsed within 6 months and those who relapsed between 6 and 12 months; those who relapsed between 6 and 12 months and those who relapsed between 12 and 18 months; and those who relapsed between 12 and 18 months and those who relapsed after 18 months. By contrast, in patients with clear cell/mucinous adenocarcinoma who were treated with platinum following a relapse, there were no significant differences in the PFS between patients who relapsed within 6 months and those who relapsed between 6 and 12 months, while there were significant differences in the PFS between those who relapsed between 6 and 12 months and those who relapsed after 12 months. With regard to the patients who relapsed after 12 months, the PFS of those with clear cell/mucinous adenocarcinoma was significantly shorter compared with the PFS of those with serous/endometrioid adenocarcinoma. Therefore, we considered it justified to classify patients with clear cell/mucinous adenocarcinoma who relapsed within 12 months as platinum-resistant and those who relapsed after 12 months as platinum-sensitive.

Details

Language :
English
ISSN :
2049-9450
Volume :
2
Issue :
2
Database :
MEDLINE
Journal :
Molecular and clinical oncology
Publication Type :
Academic Journal
Accession number :
24649335
Full Text :
https://doi.org/10.3892/mco.2013.223